RESEARCH MONOGRAPH · KDC-MN-194

Lixisenatide

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

63/100

Short-acting GLP-1 agonist that lost the market race and barely deserves the shelf space it has

Lixisenatide is honestly the GLP-1 agonist that time forgot. Sanofi developed it as a once-daily exenatide-derivative with a slightly modified C-terminus (six lysine residues added) and brought it to market as Adlyxin / Lyxumia. The pharmacology is fine. The mechanism is identical to exenatide and the other GLP-1R agonists. The problem is that by the time it got FDA approval in 2016, liraglutide was already established and semaglutide was about to dominate the entire space.

Half-life is around 3 hours, so it's a short-acting agent with strong postprandial glucose-lowering and weaker effects on fasting glucose. That's actually a reasonable pharmacological niche for postprandial-dominant diabetes, but it's a narrow indication and the combination product with insulin glargine (Soliqua / iGlarLixi) is where most of the actual clinical use lives. As a standalone agent it never really took off.

The cardiovascular outcomes trial (ELIXA, 2015) was the first GLP-1 CV outcomes study and showed neutral results in post-ACS patients, which was a perfectly fine result but didn't generate the buzz that LEADER and SUSTAIN-6 did for liraglutide and semaglutide. Cardio-protection appears to require longer receptor occupancy than lixisenatide provides.

What we like, honestly not much that's unique. It's a pharmacologically clean short-acting GLP-1 agonist, useful as a tool compound for studying acute postprandial effects vs sustained agonism, but for any chronic study you'd use semaglutide or tirzepatide instead. Discontinued from US distribution in early 2023 by Sanofi due to commercial unviability, which tells you everything about its market position.

Sourcing for research material is workable but harder than for the major GLP-1 agonists because of low commercial demand. The 44-residue peptide isn't difficult to synthesize but reference standards are less readily available, and the counterfeit risk that haunts the entire GLP-1 space applies here too with the added wrinkle that there's almost no legitimate market to validate against.

Worth keeping in the catalog? for completeness of the GLP-1 receptor agonist class, sure. As anything you'd actually choose to study over its competitors, no.

Evidence: 70
Mechanism: 85
Reliability: 70
Safety: 78
Sourcing: 60
Value: 50
Signal: 45
Staying power: 45

Plain-language summary Intrigue 60 / 100

Lixisenatide, sold as Adlyxin, is a daily GLP-1 receptor agonist with shorter duration than semaglutide. It particularly affects post-meal blood sugar. Approved for type 2 diabetes. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

GLP-1 receptor agonist

A daily-dosing GLP-1 receptor agonist FDA-approved 2016 (Adlyxin) for T2DM, structurally derived from exenatide.

Abstract

Lixisenatide (Adlyxin, Lyxumia; CAS 320367-13-3; molecular weight 4858.49) is a 44-amino-acid peptide GLP-1 receptor agonist developed by Sanofi and approved by the FDA in 2016 for T2DM. The compound is structurally derived from exenatide with a six-lysine C-terminal extension. Pharmacokinetics: plasma half-life ~3 hours; once-daily dosing. Reported research dose ranges in the literature are described in the source publications.

Mechanism of action

GLP-1 receptor agonist; exenatide-derived with hexalysine C-terminal extension.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Christensen M, et al. Lixisenatide for type 2 diabetes mellitus. Expert Opin Investig Drugs 2011.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-194

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Lixisenatide

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs